Treatment of Patients with Relapsed/Refractory Hodgkin Lymphoma

Česká verzia

Authors: H. Mociková ¹; R. Pytlík ²; L. Raida ³; A. Sýkorová ⁴; J. Marková ¹; Z. Král ⁵; P. Jindra ⁶; K. Steinerová ⁶; V. Válková ⁷; M. Trnková ⁸; B. Vacková ²; M. Trněný ^2,7; K. Indrák ³; D. Belada ⁴; J. Mayer ⁵; V. Koza ⁶; T. Kozák ¹
Authors place of work: Oddělení klinické hematologie, FN Královské Vinohrady Praha ¹; I. interní klinika VFN Praha ²; Hematoonkologická klinika, FN Olomouc ³; Klinika hematoonkologie, FN Hradec Králové ⁴; Interní hematoonkologická klinika, FN Brno ⁵; Oddělení hematoonkologie, FN Plzeň ⁶; Ústav hematologie a krevní transfuze, Praha ⁷; Národní registr kmenových buněk ČR-datacentrum ⁸
Published in the journal: Klin Onkol 2011; 24(2): 121-125
Category: Original Articles

Summary

Backgrounds:
This retrospective study evaluated treatment outcomes in patients undergoing autologous stem cell transplantation (ASCT) for relapsed/refractory Hodgkin lymphoma (HL).

Patients and Methods:
Overall, 194 HL patients treated with ASCT between 2000 and 2009 were analyzed. Survival was calculated using Kaplan-Meier method and differences in survival between subgroups with log-rank test.

Results:
Best responses observed after ASCT: 124 complete and 35 partial remissions, 2 patients with stable disease and 33 relapses/progressions. During a median follow-up of 44 months, seventy patients after ASCT progressed/relapsed. Thirty-seven patients received salvage chemotherapy only with or without radiotherapy, 25 underwent allogeneic stem cell transplantation (SCT), 4 the second ASCT and 4 refused treatment. 5-year overall survival after ASCT was 71% and progression-free survival 54%. Median survival of the 70 patients relapsing after ASCT was 16.9 months. Median survival in patients after allogeneic SCT was 31.8 months and 12.4 months in patients treated with other modalities (p = 0.21). Overall mortality was 26.3% (51/194 patients): 13.4% progressions/relapses of HL and 12.9% non-relapse mortality.

Conclusion:
Efficacy of ASCT was confirmed in 54% progression-free survivors. Median survival after ASCT failure is relatively short. There is a slightly longer overall survival after allogeneic SCT, although not statistically significant when compared to other approaches.

Key words:
Hodgkin lymphoma – relapse – salvage therapy – stem cell transplantation

Zdroje

1. Sieniawski M, Franklin J, Nogova L et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin’s lymphoma. J Clin Oncol 2007; 25(15): 2000–2005.

2. Fermé C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 2007; 357(19): 1916–927.

3. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Eng J Med 2003; 348(24): 2386–2395.

4. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993; 341(8852): 1051–1054.

5. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359(9323): 2065–2071.

6. Venkatesh H, Di Bella N, Flynn TP et al. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin’s lymphoma. Clin Lymphoma 2004; 5(2): 110–115.

7. Spencer A, Reed K, Arthur C. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J 2007; 37(11): 760–766.

8. Oki Y, Pro B, Fayad LE et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008; 112(4): 831–836.

9. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008; 141(1): 3–13.

10. Castagna L, Sarina B, Todisco E et al. Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. Biol Blood Marrow Transplant 2009; 15(4): 432–438.

11. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol 1996; 14(2): 572–578.

12. Sureda A, Robinson S, Canals C et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26(3): 455–462.

13. Josting A, Franklin J, May M et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2002; 20(1): 221–230.

14. Josting A, Reiser M, Rueffer U et al. Treatment of primary progressive Hodgkin’s and aggressive non-Hodgkin’s lymphoma: is there a chance for cure? J Clin Oncol 2000; 18(2): 332–339.

15. Santoro A, Magagnoli M, Spina M et al. Ifosfamide, gemcitabine and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 2007; 92(1): 35–41.

16. Todd T, Raj S, Camilleri D et al. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting-a new standard of care in relapsed or refractory Hodgkin lymphoma? Ann Hematol 2009; 88(11): 1107–1112.

17. Validire P, Fermé C, Brice P et al. A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin’s lymphoma patients. Anticancer Drugs 2008; 19(3): 309–315.

18. Anderlini P, Saliba R, Acholonu S et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93(2): 257–264.

19. Khouri IF, Keating M, Körbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16(8): 2817–2824.

20. Robinson SP, Sureda A, Canals C et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94(2): 230–238.

21. Josting A, Rudolph C, Mapara M et al. Cologne high--dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16(1): 116–123.

22. Bishton MJ, Lush RJ, Byrne JL et al. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol 2007; 136(5): 752–761.

23. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97(3): 616–623.

24. Schellong G, Dörffel W, Claviez A et al. Salvage therapy of progressive and recurrent Hodgkin’s disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23(25): 6181–6189.

25. Jabbour E, Hosing C, Ayers G et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007; 109(12): 2481–2489.

26. Josting A, Nogova L, Franklin J et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005; 23(7): 1522–1529.

27. Morschhauser F, Brice P, Fermé C et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008; 26(36): 5980–5987.

28. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program 2008: 326–333.

29. Moskowitz AJ, Perales MA, Kewalramani T et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009; 146(2): 158–163.

30. Smith SM, van Besien K, Carreras J et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008; 14(8): 904–912.

31. Burroughs LM, O’Donnell PV, Sandmaier BM et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14(11): 1279–1287.

32. Devetten MP, Hari PN, Carreras J et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009; 15(1): 109–117.

33. Peggs KS, Sureda A, Qian W et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007; 139(1): 70–80.

34. Thomson KJ, Peggs KS, Smith P et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008; 41(9): 765–770.